Inclusion Criteria:

- Informed consent form signed before performing any of the study's specific
procedures.

- ECOG performance status 0-2.

- Age > 18 and < 75.

- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,
greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT)
scan and MRI or greater than or equal to 2 cm by other ordinary radiographic
technique.

- Histologically confirmed diagnosis of locally advanced esophageal.

- Life expectancy of more than 3 months.

- Use of an effective contraceptive method for patients of both sexes when there is a
risk of conception and/or pregnancy.

- No serious blood producing,abnormal function of heart,lung, liver, or kidney or
immuno-deficiency

- Neutrophils ≥3×109/L, platelet count≥100×109/L and haemoglobin≥9g/dL ,Creatinine ≤
1.5 x NUL

Exclusion Criteria:

- Previous radiotherapy or chemotherapy

- Pregnant or breast-feeding women

- Drug abuse, unhealthy drug/alcohol addiction,or virus (HIV) infection

- Evidence of distant metastasis

- Participation in other clinical trials

- Patients with aphagosis, complete obstruction, fistula or deep peptic ulcer in the
esophagus, or haematemesis

- Uncontrolled psychiatric disease or seizure

- Patients not fit for the clinical trial judged by the investigators